Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07048314 · ClinicalTrials.gov registry record · Phase 1
Stem Cells for Erectile Dysfunction Post RALP
A Phase 1 study, sponsored by The Methodist Hospital Research Institute.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT07048314 is a Phase 1 study that is actively recruiting participants, run by The Methodist Hospital Research Institute. The registered enrollment target is 40 participants.
The verdict
NCT07048314, a Phase 1 study, is actively recruiting participants, sponsored by The Methodist Hospital Research Institute.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
This is a phase 1/2 single center, pilot study to assess safety and efficacy of allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) and to evaluate the timing and combination effects of active treatment versus placebo in promoting the recovery of erectile function in patients undergoing radical retropubic prostatectomy (RALP) of localized prostate cancer.
Interventions
- DRUG Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) at the doctor's office
- DRUG Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) in the OR
- DRUG Placebo in the OR
- DRUG Placebo in clinic
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2026-07-07 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07048314
The ClinicalTrials.gov registry entry for NCT07048314 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Methodist Hospital Research Institute, which has 126 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) at the doctor's office is the first listed.
NCT07048314 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07048314 about?
NCT07048314 is a clinical study titled "Stem Cells for Erectile Dysfunction Post RALP". This is a phase 1/2 single center, pilot study to assess safety and efficacy of allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) and to evaluate the timing and combination effects of active treatment versus placebo in promoting the recovery of erectile function in patients undergoing ra...
What is the current status of trial NCT07048314?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2026-07-07. Estimated completion is 2027-06-30.
What interventions are being tested in trial NCT07048314?
The interventions under investigation include: Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) at the doctor's office (DRUG), Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) in the OR (DRUG), Placebo in the OR (DRUG), Placebo in clinic (DRUG).
Who is sponsoring clinical trial NCT07048314?
This trial is sponsored by The Methodist Hospital Research Institute, which has 126 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.